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Abstract
Background: Cells of most human cancers have supernumerary centrosomes. To enable an accurate chromosome
segregation and cell division, these cells developed a yet unresolved molecular mechanism, clustering their extra
centrosomes at two poles, thereby mimicking mitosis in normal cells. Failure of this bipolar centrosome clustering
causes multipolar spindle structures and aberrant chromosomes segregation that prevent normal cell division and
lead to ‘mitotic catastrophe cell death’.
Methods: We used cell biology and biochemical methods, including flow cytometry, immunocytochemistry and
live confocal imaging.
Results: We identified a phenanthrene derived PARP inhibitor, known for its activity in neuroprotection under
stress conditions, which exclusively eradicated multi-centrosomal human cancer cells (mammary, colon, lung,
pancreas, ovarian) while acting as extra-centrosomes de-clustering agent in mitosis. Normal human proliferating
cells (endothelial, epithelial and mesenchymal cells) were not impaired. Despite acting as PARP inhibitor, the
cytotoxic activity of this molecule in cancer cells was not attributed to PARP inhibition alone.
Conclusion: We identified a water soluble phenanthridine that exclusively targets the unique dependence of most
human cancer cells on their supernumerary centrosomes bi-polar clustering for their survival. This paves the way
for a new selective cancer-targeting therapy, efficient in a wide range of human cancers.
Background
We have recently reported the selective eradication of
human triple negative mammary cancer cells MDA-231
by phenanthrene derivatives (also acting as potent inhi-
bitors of polyADP-ribose polymerases) [1]. These com-
pounds included the phenanthridines PJ-34 and Phen
and the isoquiniline Tiq-A. They were originally
designed to protect neuronal cells in the central nervous
system from cell death evoked by high activity of PARP-
1 in response to DNA damage caused by brain injury,
stroke or inflammation [2,3]. We found that these mole-
cules cause G2/M transition arrest in the cell cycle of
both mammary cancer cells MDA-231 and normal
epithelial cells MCF-10. However, while G2/M arrest
was permanent in the cancer cells, and was accompa-
nied by their massive cell death, normal mammary
epithelial cells overcame the cell cycle arrest and contin-
ued to proliferate normally in the presence of these phe-
nanthrene derivatives [1]. The most potent compound
was PJ-34, which also efficiently prevented the develop-
ment of MDA-231 xenotransplants in nude mice with-
out inducing detectable toxic effects in the animals [1].
The current results outline a mechanism that appar-
ently underlies the exclusive cytotoxicity of PJ-34 in
these human mammary cancer cells. We found that this
molecule acts as a centrosomes de-clustering agent in
cells with supernumerary centrosomes, which are most
abundant in these mammary cancer cells and in most
human cancers [4,5].
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crucial for bipolar spindle formation and accurate chro-
mosomes segregation in cells undergoing mitosis [6,7].
To accomplish these tasks, cells dividing with more than
two centrosomes have developed a yet unresolved mole-
cular mechanism, clustering their extra-centrosomes at
two poles [4,5,8]. Failure of this bipolar centrosome
assembly causes multipolar spindle structures and aber-
rant chromosomes segregation that prevent normal cell
division [5]. This may lead either to ‘mitotic slippage’
where cells ‘slip’ out of mitosis to re-enter G1 without
satisfying the spindle assembly checkpoint (SAC), or to
induction of ‘mitotic catastrophe cell death’ [5,9,10] or
‘anaphase catastrophy’ [10]. Although cell death induced
by failure to accomplish mitosis has been well documen-
ted, the underlying molecular mechanisms are still
poorly understood [5,10]
Extra centrosomes are most abundant in cells of
human solid cancers and in some of the human hemato-
logical malignancies [4,5], whereas in normal somatic
cells the number of centrosomes is restricted, via several
control mechanisms, to two centrosomes per cell
[8,9,11]. This difference between normal and cancer
human cells raised the idea of using compounds that
interfere with the bipolar clustering of extra centro-
somes to achieve selective eradication of cancer cells
without harming normal tissues [5,12].
Our findings confirm this hypothesis by identifying a
molecule, which prevents extra centrosomes clustering
in mitosis and exclusively eradicates human cancer cells
with supernumerary centrosomes without impairing
normal proliferating cells.
Methods
Cells and cell cultures
Human cancer cell lines included mammary triple nega-
tive (MDA-231) cells, lung (H1299), colon (DLD-1),
ovarian (HeyA8), and pancreatic (Panc-1) cells. These
cell-lines and the human epithelial cell line MCF-10A
were supplied by ATCC, (Manassas, VA, USA). Human
umbilical vein endothelial cells (Huvec) were supplied
by PromoCell (Heidelberg, Germany), and human pri-
mary adipose-derived mesenchymal stroma cells were
prepared from human thymus and kindly donated by
Prof Jonathan Leor (Sheba Medical Center, Israel). The
human cancer cell lines were chosen for our experi-
ments as representatives of human cancer cells with
high occurrence of extra-centrosomes.
Cancer cell lines were cultured in 6-well multi-dish
plates (Nunc; Roskilde, Denmark) and maintained in a
medium containing Dulbecco’s Modified Eagle Medium
(DMEM) containing 10% horse serum, 1% L-glutamine,
and 1% Pen-Strep-Amphotericin B (Gibco, UK). Epithe-
lial MCF-10A cells were cultured in DMEM/F12 (Gibco,
UK) containing 6% fetal bovine serum (FBS), 0.02% epi-
dermal growth factor (100 μg/ml; CytoLab, Rehovot,
Israel), 2.8% hydrocortisone (50 μM; Sigma-Aldrich),
0.1% insulin (10 mg/ml; Sigma-Aldrich), and 1% Pen/
Strep (Gibco, UK). Human endothelial cells, Huvec were
cultured in endothelial cell growth medium (cat. #
C22011; Promocell, Heidelberg, Germany) and used
within 3 passages. Human primary mesenchymal stroma
cells were prepared from thymus and cultured in
DMEM/F12 (Rhenium) containing 15% fetal bovine
serum (FBS). These cells were used within 5 passages.
Treatments
Cells were treated with phenanthrene-derived com-
pounds acting as potent PARP inhibitors: PJ-34 (N-(6-
oxo-5,6-dihydro-phenanthridin-2-yl)-N,N-dimethyl-acet-
amide), Tiq-A, (4H-thieno[2,3-c]isoquinolin-5-one), and
Phen, (6(5H)-phenanthridinone). PJ-34 and Phen were
purchased from Alexis Biochemicals (Enzo Life Sciences
International, Inc. PA, USA), Tiq-A was purchased from
Sigma-Aldrich. In addition, cells were treated with two
potent PARP inhibitors that are not phenanthrene deri-
vatives, ABT-888 (2-[(R)-2-methylpyrrolidin-2-yl]-1H-
benzimidazole-4-carboxamide) (Abbott Labs, Illinois, U.
S.A) and BSI-201 (4-iodo-3-nitrobenzamide) (BiPar, San
Francisco, CA, USA) (Figure 1).
Flow cytometry was performed with Beckton Dicken-
son machine and the FlowJo software (Tree Star, Ash-
land, OR). It was used to monitor changes in the ploidy
levels of malignant and normal cells. At the indicated
times, the cells were collected, permeabilized (75% etha-
nol in double-distilled water), and stained with propi-
dium iodide. Cell eradication and the kinetics of S-phase
entry and G2/M transition were monitored by measur-
ing the percentages of cells at the different phases. Cell
counts at the selected time periods during 120 hours
incubation indicated cell-cycle changes resulting from
treatment with the tested compounds. Untreated cells
were used as controls for each cell type at the selected
time periods.
Confocal microscope imaging and immunocytochemistry
For immuno-cytochemistry, cells were grown on glass
coverslips in the appropriate growth medium. After
treatment, the cells were fixed with 4% paraformalde-
hyde (PFA; 20 minutes) and permeabilized with 0.2%
Triton-X100 before blocking with 10% goat serum in
PBS (details were described before [13]). The cells were
immunolabeled for a and g-t u b u l i n .S p i n d l e sw e r e
labeled by antibodies directed against a-tubulin (T9026;
Sigma) and detected by secondary fluorescent antibody
Dylight (green) (Jackson ImmunoResearch Cat # 115-
485-166). Antibodies directed against g-tubulin (polyclo-
nal, T5192; Sigma) detected by secondary fluorescent
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Page 2 of 14antibody CyTM3 (red) were used for immunolabeling of
centrosomes. In some experiments centrosomes were
double labeled for g-tubulin (monoclonal, Abcam, MA,
ab11316) and for centrin1 (polyclonal, Abcam, MA,
ab11257) [14]. The percentage of multi-focal spindles
was calculated in most cases out of a total number of 20
spindles that were detected in different randomly
selected scanned samples of each of the tested cell types.
For live confocal imaging of cells, cells were trans-
fected using liposomal reagent (Jet-PI, Polyplus, #101-
10) with vectors encoding for g-tubulin-GFP (for detec-
tion of centrosomes), a-tubulin-RFP (for detection of
spindles and microtubule arrays) and for histone H2B-
RED (for detection of chromosomes). Twenty-four
hours after transfection the cells were exposed to PJ-34
(20 μM) for 18 hours, and then incubated in the pre-
sence of PJ-34 in live imaging chamber and scanned
over-night (about 15 hours) by confocal microscope
imaging. All the vectors were a gift of Prof. Michael
Brandeis, Hebrew University, Jerusalem.
Luminescent detection of ATP level in the cells was
used for quantification of cell viability. The Cell Viability
Assay Kit (Abcam, MA) enabled a rapid quantification
of viable cells in the cultures (the net result of growth
arrest, cell death and cell proliferation). This method is
based on the correlation between cell viability and ATP
production, which signals the presence of metabolically
active cells [15]. High percentage of cell death, as quan-
tified by flow cytometry, was in correlation with
decreased ATP levels in the tested cell cultures.
Figure 1 The chemical structure of the compounds tested in both cancer and benign human cells. The phenanthridines, PJ-34 and Phen,
the isoquiniline Tiq-A, and the non-phenanthrene derivatives, ABT888 and BSI-201. These compounds act as potent PARP inhibitors.
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We examined several potent PARP inhibitors, includ-
ing the phenanthrene derivatives PJ-34, Tiq-A and
Phen and the non-phenanthrene derivatives ABT-888
and BSI-201 (Figure 1) in human cancer cell types
with a high occurrence of extra-centrosomal cells
(>50%).
In our previous experiments PJ-34 caused G2/M arrest
and a massive cell death in MDA-231 mammary cancer
cells without impairing normal human mammary
epithelial MCF-10 cells [1]. Given that MDA-231 cells
have high occurrence of extra-centrosomes, and the
interference with bipolar clustering of supernumerary
centrosomes causes G2/M arrest [5,16,17], we examined
the possibility that PJ-34 affects extra-centrosomes clus-
tering in mitosis.
Our experiments disclosed a remarkable activity of PJ-
34 on disruption of the bipolar clustering of supernu-
merary centrosomes in mammary MDA-231 cancer
cells, causing distorted multi-polar spindles as early as 6
hours after PJ-34 application, followed by massive cell
death within 48-72 hours (Figures 2a, b and Additional
File 1). PJ-34 was applied only once to the cells, 24
hours after seeding, at twice to 3-times higher concen-
tration than that completely inhibiting the activity of
PARP-1 [3]. The cytotoxic activity of PJ-34 was identi-
fied in randomly selected fixed or live MDA-231 cells,
scanned by confocal microscopy (Figures 2a, b and
Additional File 1; Methods). Also, PJ-34 did not seem to
impair the structure or formation of centrosomes, as
indicated by centrosomes double labeling with centrin1
and g-tubuline (Figure 2a) and by confocal imaging of
centrosomes in live MDA-231 cells in the interphase
(Additional File 2).
These findings associated the remarkable cytotoxic
activity of PJ-34 in MDA-231 cells with de-clustering of
their extra-centrosomes in mitosis, causing multi-polar
distorted spindles and aberrant chromosomes segrega-
tion that lead to ‘mitotic catastrophe cell death’ [5].
Other phenanthrene derived molecules acting as
PARP inhibitors, Phenanthridinon (Phen), and Tiq-A
(Figure 1; [18,19]), similarly interfered with centrosomes
clustering in MDA-231 cells. However, their effect was
milder and accompanied by a lower percentage of cell
death (Figure 3).
In contrast, non-phenanthrene derivatives acting as
potent PARP inhibitors, BSI-201 and ABT888 [18,19],
did not share this capability. Even when used at high
concentrations (2-4 times higher than concentrations
completely inhibiting the activity of PARP-1) they did
not impair the bifocal clustering of extra centrosomes in
these cells (Figure 3).
To further test the suggested contribution of PJ-34 to
extra-centrosomes de-clustering, we examined its
activity in other human cancer cell-lines with high
occurrence of supernumerary centrosomes.
PJ-34 similarly eradicated the tested cells, including
lung (H1299), colon (DLD-1), ovarian (HeyA8), and
pancreatic (Panc-1) cancer cells. PJ-34 (20-30 μM)
caused G2/M arrest in these cells and a subsequent
massive cell death, observed 48-96 hours after PJ-34
application (Figures 4 and 5). In accordance, PJ-34 pre-
vented the bipolar clustering of supernumerary centro-
somes in these cells, causing multipolar spindles and
aberrant chromosomes alignment detected within 18
hours after PJ-34 application (Figure 6). For the tested
five types of cancer cell-lines, there was a significant
correlation between the fraction of cells with multi-
polar spindles and the reduction in cell viability (as indi-
cated by the reduction in ATP level) of the treated cells
(Figures 2a, 4 and 6; r = 0.92; p < 0.0001). Thus, cell
death could be attributed to de-clustering of their extra-
centrosomes.
In contrast, normal human proliferating cells were
resistant to the cytotoxic activity of PJ-34, Tiq-A and
Phen in human cancer cells. Even at the high concentra-
tions used and the long incubation periods, the most
potent compound, PJ-34, did not interfere with the cell
cycle of benign human proliferating cells. The tested
cells included human mammary epithelial cells MCF-10,
mesenchymal cells prepared from human thymus and
human umbilical vein endothelial cells (Huvec) (Figure
7). As for Huvec, PJ-34 did not affect their cell cycle
within 48 hours incubation (Figure 7). These cells did
not survive longer incubation periods even without
treatment (> 5% cell death was measured in untreated
Huvec cells after 72 hours incubation).
In these three types of benign cells, PJ-34 did not
interfere with the formation and assembly of centro-
somes (two centrosomes at the poles of bifocal spindles),
nor with chromosomes segregation. Bipolar assembly of
centrosomes, bifocal spindle formation and chromo-
somes segregation were not impaired in the normal pro-
liferating cells, even after long incubation with high
concentrations of PJ-34 (Figure 8).
Discussion
Our results suggest that the exclusive eradication of
human cancer cells with extra centrosomes by the phe-
nanthridine derivative PJ-34 is attributable to its extra-
centrosomes de-clustering activity in mitosis (Figures 2,
4, 5, 6, Additional File 1 and Additional File 2).
According to our observations, PJ-34 did not impair
centrosomes in both human normal and cancer cells,
nor did it interfere with the formation of centrosomes
in the interphase of multi-centrosomal cancer cells or
impaired the bi-polar assembly of centrosomes in mito-
sis of normal proliferating cells with two centrosomes
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Page 4 of 14Figure 2 De-clustering of supernumerary centrosomes in mitosis preceded PJ-34 induced cell death in human mammary cancer cells
MDA-231. (a) PJ-34 induced multi-polar spindles with scattered centrosomes and cell death in MDA-231 cells. Top:( Left) loss of cell viability
after treatment with PJ-34 was quantified by luminescent detection of ATP levels in the treated cells (% ATP levels in cells treated with PJ-34
relative to ATP levels of untreated, control cells) (Methods). Cells were incubated with PJ-34 (applied once at 24 hours after seeding) for 72 hours
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Page 5 of 14(Figures 2a, 8, Additional File 1 and Additional File 2).
These features may underlie its outstanding capability to
exclusively eradicate human cancer cells while keeping
normal proliferating cells un-affected (Figures 5 and 7).
Theoretically, in cancer cells with high occurrence of
extra-centrosomes (>50%) when mitosis is accompanied
by eradication of multi-centrosomal cells, an exponential
reduction of the fraction of bi-centrosomal cancer cells
is expected. In this case, the higher their proliferation
rate the more rapidly will these cancer cells be eradi-
cated by extra-centrosomes de-clustering agents.
The indicated interference of the tested phenanthrene
derivatives with the bipolar clustering of supernumerary
centrosomes was not shared by non-phenanthrene deri-
vatives acting as potent PARP inhibitors as well (Figure
3). This questions an exclusive role of PARP inhibition
in extra centrosomes de-clustering. Nevertheless, these
results could also reflect a possible, yet un-identified
selective inhibition of PARP isoforms by
phenanthridines.
Results obtained from genome-wide RNAi screen in
multi-centrosomal cells, including embryonic Drosophila
S2 cells and human malignant cells, identified genes
required to suppress multipolar mitosis. Proteins
involved in the organization and regulation of the cytos-
keleton, including Kinesin HSET/Ncd (which is not
required for polar organization in normal somatic cells)
and the four chromosomal passenger complex (CPC)
components, Aurora-B, INCENP, Survivin, and Borealin
were identified among the main proteins required for
bifocal clustering of extra-centrosomes in these cells
[12,17]. Evidence for the necessity of tankyrase-I and a
putative human PARP-16 homolog in centrosomes clus-
tering has been also provided [17,20]. PolyADP-ribosyla-
tion of tankyrase-1 may contribute to spindle bipolarity
by providing a static matrix, anchoring microtubule-
associated motor proteins and spindle proteins [17,20].
A specific role for PARP-16 in mitosis has not been
identified yet [17].
PARP proteins are present in centrosomes [21-24],
and both Aurora-B and INCENP are targets for poly-
ADP-ribosylation [22,24]. In addition, supernumerary
centrosomes were found in PARP-1 deficient cells [25].
Thus, in view of the exclusive interference of PJ-34 with
extra centrosomes de-clustering in mitosis, a possible
synergism between PARP activity and other mechanisms
underlying extra-centrosomes clustering should be
further investigated.
The indicated cytotoxic activity of the phenanthrene
derivatives in human cancer cells with high occurrence
of extra-centrosomes links for the first time between
two well known, but poorly understood phenomena;
Some anti-tumor effects of natural phenanthridines
were first described in the early fifties [26-28], and a
higher cytotoxicity of some phenanthridines in cancer
cells as compared to normal cells has been reported
before [29,30], although the underlying mechanisms
have never been understood. In addition, cell-cycle
arrest resulting from failure of centrosomes to accom-
plish bipolar clustering in multi-centrosomal cells has
been acknowledged for nearly a century [6,31,32].
Nevertheless, the causal relationship between multiple
centrosomes and malignancy has only recently been
clarified [32-35].
Mitotic-spindle microtubules are among the most
effective targets for anti-cancer therapy [5,10,17,36-39].
Therefore efforts are invested in trying to find mechan-
isms exclusively targeting mitosis in cancer cells [40-42].
Unlike the exclusive interference of PJ-34 with extra
centrosomes bi-polar clustering in mitosis (Figures 2, 3,
4, 5, 6, Additional File 1 and Additional File 2), the cur-
rently known small molecules interfering with mitosis in
(grey line) and 96 hours (black line). The mean values and standard deviations of 4 measurements in 3 different experiments are presented.
(Right) The percentage of distorted spindles with scattered centrosomes in cells treated with PJ-34 was calculated out of 20 detected spindles by
confocal scanning of randomly selected MDA-231 cells that were incubated with PJ-34 at the indicated concentrations and durations (48 hours;
grey line) and (72 hours; black line). Both untreated and treated cells were permeabilized and immunolabeled for a- and g-tubulin in 3 different
experiments, as explained below. Middle: Confocal images presenting scattered centrosomes and aberrant chromosomes arrangement in
multifocal spindles of randomly selected MDA-231 cells that were permeabilized and immunolabeled for a- and g-tubulin for the detection of
spindles and centrosomes (green and red fluorescent labeling, respectively), 18 hours after application of PJ-34 at the indicated concentrations.
Chromosomes were labeled with DAPI reagent (blue) (Methods). Bottom: Double immunolabeling of centrosomes for g-tubulin (green) and
centrin1 (red) in randomly selected MDA-231 cells. Bipolar clustering of 4 centrosomes in an untreated cell (Left) and 4 un-clustered centrosomes
in a cell treated with PJ-34 (20 μM) (Right) (Methods). (b) Live confocal imaging indicated the effect of PJ-34 on bi-polar centrosomes’ clustering
in randomly selected live MDA-231 cells. MDA-231 cells were transfected with vectors encoding for histone H2b-RED (red; for chromosomes
labeling) and for g-tubulin-GFP (green; for centrosomes labeling). Randomly selected cells were scanned overnight by confocal microscopy
without or during treatment with PJ-34 (Methods). Upper frame- Un-clustered centrosomes (Left) during mitosis preceded cell death (Right)i na
randomly selected live MDA-231 cell that was incubated with PJ-34 (20 μM) for 18 hours before scanning and during scanning (15 hours;
imaging is included in Additional File 1). Lower frame- MDA-231 cells untreated with PJ-34. (Left) Live confocal images of randomly selected live
MDA-231 cell with clustered centrosomes in anaphase. (Right) confocal image of randomly selected untreated fixed MDA-231 cell in anaphase.
This cell was permeabilized and immunolabeled for a-tubuline (green; spindles) and for g-tubuline (red; centrosomes). Chromosomes were
labeled with DAPI reagent (blue).
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Page 6 of 14cancer cells target microtubule polymerization (vinca
alkaloids, taxanes, colchicines, and also griseofulvin).
These compounds therefore impair normal cells as well,
and cause severe side effects [36-39].
The discovered potency of PJ-34 in preventing bipolar
clustering of extra centrosomes in mitosis may pave the
way for a new efficient therapy lacking intolerable side
effects, which is based on compounds that exclusively
target the unique dependence of many human cancer
cells on their supernumerary centrosomes clustering for
their survival.
Since many human cancer cells have high occurrence
of multicentrosomal cells, the exclusive cytotoxic activity
of PJ-34 in multi-centrosomal human cancer cells holds
Figure 3 The phenanthrene derivatives Phen and Tiq-A interfered with supernumerary centrosomes clustering in MDA-231 cells.
Confocal images present scattered centrosomes and aberrant arrangement of chromosomes in randomly selected fixed MDA-231 cells in
mitosis. Top: These cells were permeabilized and immunolabeled for a- and g-tubulin (labeling spindles (green) and centrosomes (red),
respectively) 24 hours after application of Tiq-A or Phen at the indicated concentrations. Bottom: Bi-polar clustering of centrosomes in randomly
selected fixed MDA-231 cells that were incubated for 48 hours with the non-phenanthrene derivatives ABT-888 and BSI-201, at the indicated
concentrations, permeabilized and immunolabeled for a- and g-tubulin. Chromosomes were labeled with DAPI reagent (blue).
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Page 7 of 14Figure 4 Eradication of human cancer cells with high occurrence of extra-centrosomes by the phenanthridine PJ-34. Top: Colon cancer
cells DLD-1, lung cancer cells H1299, ovarian cancer cells HeyA8 and pancreatic cancer cells PANC-1 were examined under light microscope in
randomly selected fields (0.02-0.03 mm
2 per field). The presented cells were either untreated (control) or incubated for 96 hours with PJ-34
applied once at 24 hours after seeding at the indicated concentrations. These are representative results of experiments that were repeated three
times for each cell line. Bottom: Changes in cells’ viability (total viable cells) were quantified by luminescent detection of ATP levels (% ATP level
in cells treated with PJ-34 relative to ATP level measured in untreated, control cells) in each of the indicated cancer cell-lines. cells were
incubated for 72 hours (grey line) and for 96 hours (black line) with PJ-34 applied once at 24 hours after seeding at the indicated concentrations
(Methods). The mean values and standard deviations of 4 measurements in each cell-line in 3 different experiments are presented.
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Page 8 of 14Figure 5 Flow cytometry indicating G2/M arrest and cell death in the multi-centrosomal human cancer cells. PJ-34 was applied 24 hours
after seeding to human colon cancer DLD-1 cells, lung cancer H1299 cells and ovarian cancer HeyA8 cells at the indicated concentrations.
Treated and control cells were analyzed 48, 72 and 96 hours after PJ-34 application (48 and 72 hours are presented only for DLD1). The effect of
PJ-34 on cell eradication (sub-G1 population) and the kinetics of S-phase entry and G2/M transition were assayed by the percentage of cells at
each of these phases. For each cell type, similar results were obtained in experiments repeated 3 times (Methods).
Castiel et al. BMC Cancer 2011, 11:412
http://www.biomedcentral.com/1471-2407/11/412
Page 9 of 14Figure 6 The phenanthridine PJ-34 prevented bi-polar clustering of extra-centrosomes in the tested human cancer cells. Top:P J - 3 4
interfered with the bifocal clustering of centrosomes in the indicated human cancer cells (DLD1, grey line, solid grey dots; H1299, grey line,
empty diamonds; HeyA8, grey line, solid black squares; PANC1, black line, empty triangles) fixed 72 hours after application of PJ-34 at the
indicated concentrations. Control and treated cells were permeabilized and immunolabeled for a- and g-tubulin, for the detection of spindles
(green) and centrosomes (red), respectively, as described below. The percentage of multi-focal spindles was calculated out of 20 spindles
detected in randomly selected fixed cells by confocal microscopy in 3 different experiments. Bottom: Confocal images indicate scattered
centrosomes and multi-focal spindles in randomly selected fixed cells in mitosis of the indicated cell-lines, 48 hours after application of PJ-34 at
the indicated concentrations. Control (untreated) and treated cells were permeabilized and immunolabeled for a- and g-tubulin (green and red,
respectively). Chromosomes were labeled with DAPI reagent (blue).
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Page 10 of 14Figure 7 The phenanthridine PJ-34 did not affect the cell-cycle of human normal proliferating cells. Flow cytometry analysis shows that
PJ-34 did not affect the cell cycle of human mammary epithelial cells MCF-10, adipose-derived mesenchymal stroma cells prepared from
thymus, and human umbilical vein endothelial cells (Huvec). Cells were incubated for the indicated periods with the indicated concentrations of
PJ-34 applied 24 hours after seeding. For each cell type, similar results were obtained in experiments repeated 3 times (Methods).
Castiel et al. BMC Cancer 2011, 11:412
http://www.biomedcentral.com/1471-2407/11/412
Page 11 of 14Figure 8 Centrosomes assembly, bifocal spindles and chromosomes segregation were not impaired by PJ-34 in normal human
proliferating cells. Epithelial cells MCF-10, mesenchymal stroma cells and endothelial cells (Huvec) were scanned by confocal microscope after
72 hours incubation in the absence or presence of 20 μM PJ-34, applied 24 hours after seeding at the indicated concentrations. Top: Percentage
of multi-focal spindles (approximately zero) in randomly selected fixed cells was calculated out of at least 20 detected spindles in 3 different
experiments performed with each cell type (MCF-10, black line, solid black square; mesenchymal cells, grey line, solid grey diamond; Huvec, grey
line, grey triangle). Control (untreated) and treated cells were permeabilized and immunolabeled for a- and g-tubulin for the detection of
spindles and centrosomes, respectively, as described below. Bottom: Confocal images of randomly selected cells in mitosis, untreated (control)
cells, and cells that were incubated with PJ-34 for 72 hours at the indicated concentrations. Untreated cells and cells treated with PJ-34 were
permeabilized and immunolabeled for a- and g-tubulin (green and red, respectively) for detection of spindles and centrosomes, respectively.
Chromosomes were labeled with DAPI reagent (blue).
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Page 12 of 14promise as a therapeutic tool for a selective chemother-
apy in a wide range of human cancers, beyond the cur-
rently used selective therapeutic tools targeting specific
genes/proteins that affect few cancer cell types [43-45].
Conclusion
The identification of a molecule exclusively targeting the
unique dependence of most human cancer cells on their
supernumerary centrosomes bi-polar clustering for their
survival, paves the way for a new highly selective can-
cer-targeting therapy, efficient in a wide range of human
cancers.
Additional material
Additional file 1: Live confocal imaging of MDA-231 cell in mitosis
in the presence of the phenanthridine PJ-34. Mitosis with scattered
centrosomes ended by cell death in a randomly selected MDA-231 cell
that was incubated for 18 hours with PJ-34 (20 μM) applied 24 hours
after transfection by the indicated vectors, and then scanned over-night
(approximately 15 hours) in the presence of PJ-34 by confocal
microscope. Cells were transfected by vectors encoding for g-tubulin-GFP
(for labeling of centrosomes; green) and for histone H2B-RED (for
labeling of chromosomes; red).
Additional file 2: Live confocal imaging of MDA-231 cell in
interphase in the presence of the phenanthridine PJ-34. Interaction
between centrosomes in a randomly selected MDA-231 cell in
interphase. This cell was incubated with PJ-34 (20 μM, 18 hours
incubation) applied 24 hours after transfection by vectors encoding for g-
tubulin-GFP (green, for labeling of centrosomes) and for a-tubulin-RFP
(red, for labeling of microtubule arrays in the cytoskeleton) and scanned
overnight in the presence of PJ-34 (approximately 15 hours) by confocal
microscope.
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